Latest Insider Transactions at Avrobio, Inc. (AVRO)
This section provides a real-time view of insider transactions for Avrobio, Inc. (AVRO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AVROBIO, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AVROBIO, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 05
2025
|
Timothy A Springer |
BUY
Open market or private purchase
|
Indirect |
660,000
+40.49%
|
$33,000,000
$50.0 P/Share
|
|
Feb 05
2025
|
Timothy A Springer |
BUY
Open market or private purchase
|
Direct |
129,294
+2.97%
|
$6,981,876
$54.14 P/Share
|
|
Feb 05
2025
|
Daniel Lochner Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
4,617
+50.0%
|
$249,318
$54.14 P/Share
|
|
Feb 04
2025
|
Alise Reicin Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,047
+14.4%
|
-
|
|
Feb 04
2025
|
Marcella K. Ruddy Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,876
+26.36%
|
-
|
|
Feb 04
2025
|
Daniel Lochner Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,074
+50.0%
|
-
|
|
Feb 04
2025
|
Marc Schwabish Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,023
+42.82%
|
-
|
|
Feb 04
2025
|
Peter Mc Namara Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,141
+34.05%
|
-
|
|
Jan 28
2025
|
Marc Schwabish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,700
+36.49%
|
$5,400
$2.38 P/Share
|
|
Dec 09
2024
|
Marc Schwabish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$4,000
$2.38 P/Share
|
|
Dec 04
2024
|
Alise Reicin Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,717
+6.17%
|
-
|
|
Dec 03
2024
|
Peter Mc Namara Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+19.79%
|
$7,000
$2.38 P/Share
|
|
Oct 22
2024
|
Timothy A Springer |
BUY
Open market or private purchase
|
Direct |
300,000
+6.82%
|
$9,900,000
$33.59 P/Share
|
|
Sep 26
2024
|
Timothy A Springer |
BUY
Open market or private purchase
|
Direct |
50,000
+0.33%
|
$1,450,000
$29.57 P/Share
|
|
Sep 24
2024
|
Timothy A Springer |
BUY
Other acquisition or disposition
|
Indirect |
186,134
+50.0%
|
-
|
|
Sep 24
2024
|
Timothy A Springer |
BUY
Other acquisition or disposition
|
Direct |
1,054,759
+21.97%
|
-
|
|
Sep 24
2024
|
Timothy A Springer |
SELL
Other acquisition or disposition
|
Indirect |
1,240,893
-80.0%
|
-
|
|
Jun 20
2024
|
Braden Michael Leonard |
BUY
Other acquisition or disposition
|
Direct |
33,333
+50.0%
|
-
|
|
Jun 20
2024
|
Braden Michael Leonard |
BUY
Other acquisition or disposition
|
Indirect |
400,355
+50.0%
|
-
|
|
Jun 20
2024
|
Stefan Vitorovic |
BUY
Grant, award, or other acquisition
|
Indirect |
1,028,674
+50.0%
|
-
|
|
Jun 20
2024
|
Timothy A Springer |
BUY
Grant, award, or other acquisition
|
Indirect |
1,551,116
+50.0%
|
-
|
|
Jun 20
2024
|
Timothy A Springer |
BUY
Grant, award, or other acquisition
|
Direct |
2,692,005
+50.0%
|
-
|
|
Jun 20
2024
|
Praveen P. Tipirneni |
BUY
Grant, award, or other acquisition
|
Direct |
3,037
+50.0%
|
-
|
|
Jun 20
2024
|
Terrance Mcguire |
BUY
Grant, award, or other acquisition
|
Indirect |
1,157,976
+50.0%
|
-
|
|
Jun 20
2024
|
Peter Mc Namara Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,688
+50.0%
|
-
|
|
Jun 20
2024
|
Marcella K. Ruddy Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,065
+50.0%
|
-
|
|
Jun 20
2024
|
Christian Cortis Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
126,368
+50.0%
|
-
|
|
Jun 20
2024
|
Alise Reicin Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
124,530
+50.0%
|
-
|
|
Jun 20
2024
|
Alise Reicin Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
166,580
+50.0%
|
-
|
|
May 14
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
296,882
+5.86%
|
$296,882
$1.3 P/Share
|
|
May 13
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
469,753
+5.12%
|
$469,753
$1.25 P/Share
|
|
Feb 05
2024
|
Azadeh Golipour Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,232
-17.96%
|
$12,232
$1.2 P/Share
|
|
Feb 05
2024
|
Steven Avruch Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,812
-32.93%
|
$10,812
$1.2 P/Share
|
|
Feb 05
2024
|
Erik Ostrowski Interim CEO, President and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,099
-30.91%
|
$13,099
$1.2 P/Share
|
|
Feb 05
2024
|
Essra Ridha Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,953
-51.63%
|
$16,953
$1.2 P/Share
|
|
Feb 01
2024
|
Azadeh Golipour Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,334
+35.41%
|
-
|
|
Feb 01
2024
|
Steven Avruch Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,834
+50.0%
|
-
|
|
Feb 01
2024
|
Erik Ostrowski Interim CEO, President and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,084
+48.61%
|
-
|
|
Feb 01
2024
|
Essra Ridha Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,834
+50.0%
|
-
|
|
Jun 12
2023
|
Azadeh Golipour Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,574
-7.7%
|
$5,574
$1.2 P/Share
|
|
Jan 24
2023
|
Geoffrey Mackay President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
45,999
+19.66%
|
$0
$0.91 P/Share
|
|
Dec 28
2022
|
Geoffrey Mackay President & CEO |
BUY
Bona fide gift
|
Indirect |
245,123
+35.51%
|
-
|
|
Dec 28
2022
|
Geoffrey Mackay President & CEO |
SELL
Bona fide gift
|
Direct |
245,123
-63.32%
|
-
|
|
Dec 23
2022
|
Geoffrey Mackay President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
142,013
+26.84%
|
$0
$0.41 P/Share
|
|
Jul 07
2021
|
Philip J. Vickers Director |
BUY
Open market or private purchase
|
Direct |
4,800
+50.0%
|
$38,400
$8.35 P/Share
|
|
Feb 17
2021
|
Phillip B. Donenberg |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$22,000
$11.71 P/Share
|
|
Dec 24
2020
|
Geoffrey Mackay President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+28.98%
|
$0
$0.41 P/Share
|